Covid-19 has forced many startups to change course in favor of funding, highlighting the importance of #telehealth within the #biotech space. Machine Learning has become a necessary digital tool towards ensuring business continuity. labiotech.eu/interview/euro…

Today the #FDA determines the approval of #Aducanumab. The New York Times published a piece addressing the drug's pros and cons and two other treatment options that are showing promising data in case it is not approved. nytimes.com/2021/06/05/hea…

As companies within the #biotech and #LifeSciences sectors start planning for their next fundraising efforts, the need for a firm like with #InvestorRelations capabilities like Trophic Communications is crucial.

In the wake of the Covid-19 pandemic, companies like Mat. were able to launch successful #IPOlistings, proving there is keen interest from investors in the #biotech space. Checkout the Labiotech.eu article on whether this "trend" is potentially just the beginning

Great article from FierceBiotech examining the efforts made by #biotech and #phama companies to make #DiversityandInclusion a priority and how information can be used in targeted programming and #SocialMedia outreach to achieve higher results. fiercebiotech.com/biotech/divers…

Great Article on how scientists and farmers are using social media to combat #misinformation posts. Platforms such as LinkedIn and Twitter can be valuable tools for #biotech professionals. bit.ly/3jbca7L

A strong team and a compelling #comunications strategy are vital for any #biotech looking to secure institutional #investors to raise their US value. lifescienceleader.com/doc/how-europe…

“When you’re the VC, you’re kind of the kingmaker ... I felt like the entrepreneur needed someone to reach their hand out and say, ‘I’m going to help you with this.’” -- Chris Garabedian. This week, Rowan Walrath reports on biotech's new funding models: bizjournals.com/boston/news/20…

A great article by @VirginiaGewin about the online initiative recognizing the contributions of black scientists and their increasing roles within the various areas of clinical research. Very proud to be #BlackinBiotech #diversity #inclusion

Check out this article on how the use of #socialmedia is defined by the value, relevance, & credibility of the content it conveys. bit.ly/3neQon0

So happy to be apart of this amazing team of communicators and celebrate Trophic's 4th #anniversary. I look forward to what the next year has in store!

#Drugregulations present major challlenges for EU companies hoping for success in the US market. companies require a keen #commercialisation strategy, customizable to the needs of your specific drug. Check out this insightful piece in pharmaphorum bit.ly/3l4jTq8

Check out this great article from Labiotech.eu on how companies such as Osivax are leading the charge in generating #universalvaccines that can protect the population from all current and future strands of #Covid19. labiotech.eu/trends-news/em…

Congratulations to #Modra Pharmaceuticals on the announcement of Positive Phase 2b data evaluating it's lead candidate #ModraDoc006, an oral #taxane approach for patients living with #mCRPC linkedin.com/feed/update/ur…

So excited that I finally get to unveil my first solo website project. Thank you to the Trophic Communications team for trusting me to see it through and thank you to Ante and his team at Imagemakers Creative for helping me bring the vision to life.

In 2020 biotech IPOs continued to break and establish new records, as more startups went public and raised more cash than ever before. In 2H of 2021, we saw the performance of biotech IPOs plummet. biopharmadive.com/news/biotech-i… via BioPharma Dive

While the pace of new #SPAC offerings seem to have slowed in the second quarter of 2021, they are still positioned as an attractive option for private #biotech & #pharma companies in need of rapid access to capital thepharmaletter.com/article/why-ar…

“In the last two-to-three years, the whole biotech environment has changed dramatically. In America, until last year, there were a lot of companies going public, and they didn’t need to do deals, so it was all on their own terms" biocentury.com/article/643149…

Well said... an investment in #diversity provides access to a wealth of untapped potential & future opportunities to innovate

“The diversity in our clinical trials must mirror the patient communities the treatment hopes to serve,” Health equity innovation must go beyond the science - endpts.com/sp/health-equi…